Covalent inhibitors of CDK-7

1. A method of treating a neoplastic disease, comprising administering to a subject in need thereof an effective amount of a compound of Formula (I), or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof:

wherein

A is cycloalkyl, heterocycloalkyl, cycloalkenyl, heterocycloalkenyl, aryl, heteroaryl, fused hetero-bicyclic, or spiro-heterocyclic;

each of B, and C, independently, is cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, or heteroaryl;

each of Z 1 , Z 2 , Z 3 , and Z 4 independently, is a bond, (CR a R b ) p , (CR a R b ) p N(R a )(CR a R b ) q , N(R a )(CR a R b ) q N(R a ), (CR a R b ) p O(CR a R b ) q , (CR a R b ) p C═C(CR a R b ) q , (CR a R b ) p C≡C(CR a R b ) q , C(R a )═N, O, S, C(O), N(R a ), S(O 2 ), OC(O), C(O)O, OSO 2 , S(O 2 )O, C(O)S, SC(O), C(O)C(O), C(O)N(R a ), N(R a )C(O), S(O 2 )N(R a ), N(R a )S(O 2 ), OC(O)O, OC(O)S, OC(O)N(R a ), OC(O)N(R a )(CR a R b ) p+1 N(R a )(CR a R b ) q , N(R a )C(O)O, N(R a )C(O)S, N(R a )C(O)N(R b ), (CR a R b ) p N(R a )C(O)(CR a R b ) q , or (CR a R b ) p C(O)N(R a )(CR a R b ) q ;

each of m, n, p, and q independently, is 0, 1, 2, 3, or 4;

Warhead is

L 1 is N(R 7 ) if the atom which L 1 connects to ring A is a carbon atom; or L 1 is a direct bond if ring A is a heterocycloalkyl, heterocycloalkenyl, or heteroaryl and the atom which L 1 connects to ring A is a nitrogen atom;

L 2 is (CR a R b ) S CH═HC(CR a R b ) r in which each of r, and s independently, is 1, 2, 3, or 4;

each of W 1 , and W 2 independently, is C(R 4 ) or N;

each of R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 , independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, nitro, oxo, cyano, —OR a , —SR a , —NR b R c , —C(O)R a , —S(O)R a , —SO 2 R a , —P(O)R b R c , —C(O)N(R b )R a , —N(R b )C(O)R c , —C(O)OR a , —OC(O)R a , —SO 2 N(R b )R c , —N(R b )SO 2 R c , -alkyl-R a , -alkyl-C(O)R a , -alkyl-NR b R c , -alkyl-C(O)N(R b )R c , -alkyl-N(R b )C(O), or -alkyl-N(R b )SO 2 R c ; and

each of R a , R b , R a , R b , and R c , independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, aryl, heteroaryl, halo, cyano, amine, nitro, hydroxy, —C(O)NHOH, alkoxy, alkoxyalkyl, haloalkyl, hydroxyalkyl, aminoalkyl, alkylcarbonyl, alkoxycarbonyl, alkylcarbonylamino, dialkylamino, or alkylamino.

2. The method according to claim 1 , wherein the compound is represented by Formula (II):

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof, in which

each of Z 1 , Z 2 , Z 3 , and Z 4 independently, is a bond, (CH 2 ) p , (CH 2 ) p NR a (CH 2 ) q , NR a (CH 2 ) q NR a , (CH 2 ) p O(CH 2 ) q , CH═N, O, S, C(O), NH, S(O 2 ), OC(O), C(O)O, OSO 2 , S(O 2 )O, C(O)S, SC(O), C(O)C(O), C(O)NH, NHC(O), S(O 2 )NH, NHS(O 2 ), OC(O)O, OC(O)S, OC(O)NH, OC(O)NH(CH 2 ) p+1 NH(CH 2 ) q , NHC(O)O, NHC(O)S, NHC(O)NH, (CH 2 ) p NHC(O)(CH 2 ) q , or (CH 2 ) p C(O)NH(CH 2 ) q ; R 1 is H, alkyl, or alkyl-NR b R c ; and each of R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 , independently, is H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, halo, nitro, oxo, cyano, —OR a , —SR a , —NR b R c , —C(O)R a , —SO 2 R a , —C(O)NHR c , —NHC(O)R c , —SO 2 NHR c , —NHSO 2 R c , -alkyl-R a , -alkyl-C(O)R a , -alkyl-NHR c , -alkyl-C(O)NHR c , -alkyl-NHC(O), or -alkyl-NHSO 2 R c .

3. The method according to claim 2 , wherein the compound is represented by Formula (III):

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof, in which t is 0, 1, 2, 3 or 4; R 1 is H, low alkyl, or low alkyl-NR b R c ; each of R 3 , R 4 , and R 5 , independently, is H, alkyl, alkenyl, alkynyl, halo, or haloalkyl; and M is (CH 2 ) p , O, or N(R a ).

4. The method according to claim 3 , wherein the compound is represented by Formula (IV):

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof.

5. The method according to claim 4 , wherein R 1 is H, —CH 3 , or CH 2 —N(CH 3 )CH 3 ; R 4 is H, CH 3 , CF 3 , CN, or halo.

6. The method according to claim 1 , wherein the compound is

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof.

7. The method according to claim 1 , wherein the compound is

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof.

8. The method according to claim 1 , wherein the compound is

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof.

9. The method of claim 1 , wherein the neoplastic disease is lung cancer, head and neck cancer, central nervous system cancer, prostate cancer, testicular cancer, colorectal cancer, pancreatic cancer, liver cancer, stomach cancer, biliary tract cancer, esophageal cancer, gastrointestinal stromal tumor, breast cancer, cervical cancer, ovarian cancer, uterine cancer, leukemia, lymphomas, multiple myeloma, melanoma, basal cell carcinoma, squamous cell carcinoma, bladder cancer, renal cancer, sarcoma, mesothelioma, thymoma, myelodysplastic syndrome, or myeloproliferative disease.

10. The method of claim 1 , wherein the neoplastic disease is small cell lung cancer.

11. The method according to claim 1 , wherein the compound is

or an N-oxide thereof, a pharmaceutically acceptable salt, polymorph, tautomer, stereoisomer, or an isotopic form thereof.

12. The method according to claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

13. The method according to claim 2 , wherein the compound is represented by Formula (III),

or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein

t is 0, 1, 2, 3 or 4; R 1 is H, low alkyl, or low alkyl-NR b R c ; each of R 3 , R 4 , and R 5 , independently, is H, alkyl, alkenyl, alkynyl, halo, or haloalkyl; and M is O or N(R a ).

14. The method according to claim 3 , wherein the compound is represented by Formula (IV),

or an N-oxide thereof, or a pharmaceutically acceptable salt thereof.

15. The method according to claim 14 , wherein R 1 is H, —CH 3 , or CH 2 —N(CH 3 )CH 3 ; R 4 is H, CH 3 , CF 3 , CN, or halo.

16. The method according to claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The method according to claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

18. The method according to claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.